Roche’s Kadcyla sales KRW 70 bil…unrivaled lead in ADC mkt
By Nho, Byung Chul | translator Kang, Shin-Kook
24.05.28 05:50:40
가나다라
0
Daiichi Sankyo’s Enhertu follows the lead with KRW 20.4 billion in sales…Takeda’s Adcetris posts KRW 9.8 billion
Pfizer and Gilead race to acquire Seagen and Immunomedics, respectively, to develop and dominate the ADC market
Roche’s Kadcyla continues to remain the unrivaled lead in the domestic ADC (Antibody-Drug Conjugate) drug market, accounting for 60% share of the KRW 120 billion market.
Based on drug distribution performance, the domestic ADC drug market was valued at KRW 113.8 billion last year, of which Kadcyla (treatment for HER2-positive metastatic breast cancer) accounted for KRW 75.8 billion, maintaining the top rank in the market ever since its launch.
Kadcyla’s sales in 2019, 2020, 2021, and 2022 were in the range of KRW 35.4 billion, KRW 43.5 billion, KRW 52.7 billion, and KRW 51.8 billion, respectively. In second place is Daiichi Sankyo's Enhertu (treatment for HER2-positive breast c
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)